adenosine has been researched along with Acute Coronary Syndrome in 518 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (4.44) | 29.6817 |
| 2010's | 473 (91.31) | 24.3611 |
| 2020's | 22 (4.25) | 2.80 |
| Authors | Studies |
|---|---|
| Serebruany, V; Tanguay, JF | 1 |
| Börner, MS; Castro, JJ; López, F; Pellegrini, A; Salzberg, S | 1 |
| Jalbani, J; Karim, M; Khan, KA; Kumar, D; Kumar, R; Qamar, N; Qayyum, D; Saghir, T; Sial, JA; Yasin, U | 1 |
| Chan, YH; Ganguly, A; Hwa, K; Li, Z; Ling, XB; Su, KJ; Tam, CF; Tse, HF; Wong, YK; Zhu, X | 1 |
| Abo Dena, AS; El-Sherbiny, IM; Kabil, MF | 1 |
| Gremmel, T; Huber, K; Panzer, B; Panzer, S; Wadowski, PP | 1 |
| DE Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Rognoni, A; Suryapranata, H; Verdoia, M | 1 |
| Aurigemma, C; Bianchini, E; Burzotta, F; Ciliberti, G; Crea, F; D'Amario, D; Galli, M; Laborante, R; Leone, AM; Montone, RA; Princi, G; Restivo, A; Rodolico, D; Romagnoli, E; Trani, C; Vergallo, R; Zito, A | 1 |
| Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH | 1 |
| Cui, Y; Guo, L; Guo, N; Huang, J; Huang, Y; Jiang, J; Li, J; Liu, Y; Liu, Z; Mu, G; Song, H; Wang, Z; Xiang, Q; Xie, Q; Yang, G; Yuan, D; Zhang, H; Zhou, S | 1 |
| Libby, P; Nakao, T | 1 |
| Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS | 1 |
| Amaradasa, K; Bancroft, S; Dimofte, T; Hindle, MS; Hutchinson, JL; Johnson, T; Keith, M; Khalil, J; Mundell, SJ; Naseem, K; Roberts, T | 1 |
| de Waard, GA; Escaned, J; Fernández-Ortiz, A; Knaapen, P; Koo, BK; Lauri, FM; Lee, JM; Macaya, C; McInerney, A; Mejía-Rentería, H; van der Hoeven, NW; van Royen, N | 1 |
| Briffa, NP; Hanson, J; Judge, HM; Ow, KW; Parker, WAE; Porter, MM; Storey, RF; Thomas, MR | 1 |
| Daiber, A; Gori, T; Jurk, K; Koenig, J; Lackner, KJ; Münzel, T; Schnorbus, B; Warnke, S | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y | 1 |
| De Luca, G; Gioscia, R; Kedhi, E; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M; Viglione, F | 1 |
| Marciniak, TA; Serebruany, VL; Tanguay, JF | 1 |
| Adriaans, BP; Bekkers, SCAM; Bijvoet, GP; Crijns, HJGM; Gerretsen, SC; Heijman, J; Kim, RJ; Mingels, AMA; Schalla, S; Smulders, MW; Theunissen, RALJ; van Cauteren, YJM; van Kuijk, SMJ; Wildberger, JE | 1 |
| Dong, Z; Pan, L; Zhai, H; Zhang, B | 1 |
| Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S | 1 |
| Akkaif, MA; Daud, NAA; Ibrahim, B; Ng, ML; Sha'aban, A; Sk Abdul Kader, MA | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Bae, MH; Chae, SC; Cho, Y; Jang, SY; Kim, CY; Kim, N; Lee, JH; Park, HS; Yang, DH | 1 |
| Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Kanic, V; Kanic, Z; Kompara, G; Markota, A; Penko, M; Vollrath, M | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Hua, YH; Li, JN; Liu, C; Liu, J; Song, L; Tan, Y; Wu, Y; Yan, HB; Yang, YM; Zhao, HJ; Zhou, P | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Baber, U; Vogel, B | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Cai, S; Chen, L; Huang, S; Jiang, X; Mo, E; Tan, Q; Xie, S; Xu, J; Zhang, T | 1 |
| Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM | 3 |
| Almendro-Delia, M; Arboleda-Sánchez, JA; Butrón-Calderón, M; de la Chica-Ruiz Ruano, R; de la Torre-Prados, MV; García-Alcántara, Á; García-Guerrero, A; García-Rubira, JC; Hidalgo-Urbano, R; Reina-Toral, A | 1 |
| Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO | 1 |
| Becker, RC; Cannon, CP; Davoudi, F; Diercks, DB; Himmelmann, A; James, SK; Lim, ST; Pollack, CV; Schulte, PJ; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Christoph, M; Ende, G; Ibrahim, K; Jellinghaus, S; Loehn, T; Mierke, J; Pfluecke, C; Poitz, DM; Quick, S; Richter, B; Schoener, L; Speiser, U; Strasser, RH | 1 |
| Baber, U; Badimon, JJ; Chen, K; Escolar, G; Fuster, V; Jimenez Britez, G; Lam, DW; Linares-Koloffon, CA; Rey-Mendoza, J; Sartori, S; Smith, DA; Zafar, MU | 1 |
| Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N | 1 |
| Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J | 1 |
| Alexopoulos, D; Goudevenos, J; Hamilos, M; Kanakakis, J; Kochiadakis, G; Lekakis, J; Petousis, S; Sitafidis, G; Skalidis, E; Vardas, PE; Vavouranakis, M; Xanthopoulou, I | 1 |
| Cho, JY; Cho, SA; Hong, SJ; Jeong, HS; Joo, HJ; Kim, JH; Lee, SH; Lim, DS; Park, JH; Yu, CW | 1 |
| Gurbel, PA; Jeong, YH; Tantry, US | 1 |
| Bash, LD; Patel, MD; Simpson, RJ; Vyas, A | 1 |
| Fairley, S; Harding, SA; Holley, A; Larsen, PD; Simmonds, M; Wilkins, B | 1 |
| Han, Y; Li, C; Li, J; Li, Y; Qi, J; Tang, Y; Wang, H | 1 |
| Cattabiani, MA; De Palma, R; Guastaroba, P; Marino, M; Menozzi, A; Rasia, M; Solinas, E; Tadonio, I; Vignali, L | 1 |
| Dixon, SR; Dupree, JM; Gurm, HS; Khandelwal, A; LaLonde, T; Seth, M; Song, C; Sukul, D; Wohns, D | 1 |
| Chen, Y; Liu, J; Qin, L; Wang, X; Xi, S; Yin, T; Zhou, S | 1 |
| Abdulbaki, A; Dahal, K; Katikaneni, P; Modi, K; Watti, H; Zabher, HG | 1 |
| Lund, LH; Savarese, G | 1 |
| Carugo, S; Castini, D; Cazzaniga, S; Centola, M; Ferrante, G; Lucreziotti, S; Persampieri, S; Salerno-Uriarte, D; Sponzilli, C | 1 |
| Abu-Assi, E; Calvo-Iglesias, F; Cambronero-Sánchez, F; Cobas-Paz, R; Flores-Blanco, PJ; Iñiguez-Romo, A; Januzzi, JL; Leithold, G; Manzano-Fernández, S; Raposeiras-Roubin, S; Rodríguez Serrano, AI; Valdés, M | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Ding, P; Han, W; Jin, LM; Jin, ZG; Li, TC; Li, Y; Li, YT; Liu, HL; Liu, Y; Luo, JP; Ma, HY; Ren, YH; Tang, Q; Wang, B; Wang, MS; Wei, YJ; Yang, SL; Zhang, J; Zhang, JJ | 1 |
| Alexandre, J; Beygui, F; du Cheyron, D; Goursaud, S; Leclerc, M; Roule, V; Valette, X | 1 |
| Effron, MB; Keller, SY; McCollam, PL; Molife, C; Murphy, B; Nair, KV; Nordstrom, BL; Page, RL; Simeone, JC; Vetrovec, GW; Zhu, Y | 1 |
| Bundhun, PK; Huang, F; Shi, JX | 1 |
| He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z | 1 |
| Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y | 1 |
| Danielak, D; Główka, F; Karaźniewicz-Łada, M | 1 |
| Cohen, MG; Gulati, R; Kwan, T; Pancholy, S; Patel, T; Shah, S | 1 |
| Berthe, A; Diaby, V; Ezendu, K; Okere, AN | 1 |
| Hess, S; Jesel, L; Kibler, M; Marchandot, B; Messas, N; Meyer, N; Morel, O; Ohlmann, P; Ristorto, J; Schaeffer, M; Tuzin, N | 1 |
| Berti, S; Bolognese, L; D'Ascenzo, F; De Luca, L; De Servi, S; Gallo, P; Granatelli, A; Gulizia, MM; Musumeci, G; Pennacchi, M; Rigattieri, S | 1 |
| He, B; Liu, Y; Tobe, RG; Wu, B | 1 |
| Safiullina, ZM; SHalaev, SV | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Karagiannis, A; Ortega-Paz, L; Valgimigli, M; Windecker, S | 1 |
| Akkerhuis, KM; Ariotti, S; Brugaletta, S; Gianni, U; Janssens, G; Karagiannis, A; Leonardi, S; Ortega-Paz, L; Rimoldi, SF; Valgimigli, M; van den Berge, JC; van Leeuwen, M; Windecker, S | 1 |
| Baracioli, LM; Giugliano, RP; Nicolau, JC | 1 |
| Borawski, JB; Kim, HW; Kim, RJ; Limkakeng, AT; Painter, DM; Ziegler, CE | 1 |
| Adamski, P; Barańska, M; Buszko, K; Gorog, DA; Kubica, J; Navarese, EP; Niezgoda, P; Ostrowska, M; Paciorek, P; Sikora, J | 1 |
| Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM | 1 |
| Carreras, F; Díaz-Villanueva, J; Estofán, M; Gómez-Revelles, S; López-Lima, I; Pons-Lladó, G; Pujadas, S; Rossello, X; Sciarresi, E | 1 |
| Barańska, M; Bernd, J; Buszko, K; Gorog, D; Kubica, J; Marszałł, MP; Navarese, EP; Niezgoda, P; Pstrągowski, K; Sikora, J; Siller-Matula, J; Skibińska, N; Sroka, W | 1 |
| De Lorenzo, A; Dutra, M; Mattos, MA; Rey, HCV; Tibirica, E | 1 |
| Daemen, J; de Jaegere, P; Diletti, R; Lemmert, ME; Masdjedi, K; van Bommel, RJ; van Mieghem, NM; van Zandvoort, L; Wilschut, J; Zijlstra, F | 1 |
| Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP | 1 |
| Avetisyan, EA; Merkulova, IA; Staroverov, II | 1 |
| Henriksson, M; Janzon, M | 1 |
| Dinicolantonio, JJ; Serebruany, VL | 3 |
| Asseburg, C; Giannitsis, E; Katus, H; Theidel, U | 1 |
| Hauge, J; Kragh, R; Poulsen, BK | 1 |
| Alexopoulos, D; Davlouros, P; Mavronasiou, E; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
| Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C | 1 |
| Becker, RC; Cannon, CP; Harrington, RA; James, SK; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 2 |
| Wang, H; Wang, WE; Wang, X; Zeng, C | 1 |
| Ren, J; Steiner, JB; Wu, Z | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| Nilsen, DW | 1 |
| Coleman, CI; Limone, BL | 2 |
| Abtahian, F; Hu, S; Jang, IK; Jia, H; Kato, K; McNulty, I; Tian, J; Vergallo, R; Yonetsu, T | 1 |
| Enar, R | 1 |
| Göddertz, R | 1 |
| Barnay, P; Berbis, J; Bessereau, J; Bonello, L; Camaleonte, M; Camilleri, E; Dignat-George, F; Frere, C; Helaf, O; Laine, M; Michelet, P; Paganelli, F; Pansieri, M; Peyre, JP; Toesca, R | 1 |
| DiNicolantonio, JJ; Serebruany, VL; Tomek, A | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Kakkavas, A; Koutsogiannis, N; Mavronasiou, E; Moulias, A; Xanthopoulou, I | 1 |
| Huber, K; Lip, GY | 1 |
| Wheatcroft, S | 1 |
| Berger, JS | 1 |
| Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C | 1 |
| Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D | 1 |
| Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 2 |
| DiNicolantonio, JJ; Tomek, A | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Aylward, PE; Sinhal, AR | 1 |
| Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Aylward, P; Brandrup-Wognsen, G; Brilakis, ES; Claeys, MJ; Cools, F; Cornel, JH; Held, C; Himmelmann, A; James, SK; Lewis, BS; Meier, B; Stevens, SR; Wallentin, L; Weaver, D | 1 |
| Gasche, D; Greiner, RA; Meier, B; Ulle, T | 1 |
| Ecob, R; Hossain, R; Joshi, RR; Judge, HM; Karunakaran, A; Morton, AC; Storey, RF; Wales, C; Walker, JV | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Bansilal, S; Bonaca, MP; Sabatine, MS | 1 |
| Barnay, P; Berbis, J; Bessereau, J; Bonello, L; Camilleri, E; Dignat-George, F; Frère, C; Helal, O; Laine, M; Michelet, P; Paganelli, F; Pansieri, M; Ronsin, O; Toesca, R | 1 |
| Becker, RC; Cannon, CP; Cornel, JH; Giannitsis, E; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lindholm, D; Mahaffey, KW; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L; Wernroth, L | 1 |
| Campbell, CL; Moliterno, DJ | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Lambert, M; Morange, P; Pankert, M; Quilici, J; Verdier, V | 2 |
| Horowitz, JD; Karnon, JD; Pekarsky, B; Sorich, MJ; Sorich, W; Wiese, MD | 1 |
| Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F | 1 |
| Pizzuto, F; Voci, P | 1 |
| Becker, RC; Cannon, CP; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HS; Mahaffey, KW; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| De Franco, AC; Oldridge, N | 1 |
| Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I | 1 |
| Hartmark-Hill, JR; Tsang, K | 1 |
| Angiolillo, DJ; Antoniucci, D; Bernlochner, I; Hamm, C; Jaitner, J; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Neumann, FJ; Richardt, G; Ruf, J; Schömig, G; Schühlen, H; Schulz, S; Schunkert, H; von Merzljak, B | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Stavrou, K; Xanthopoulou, I | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R | 1 |
| Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D | 2 |
| Serebruany, VL | 9 |
| Hirschl, MM | 1 |
| Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ | 1 |
| Angiolillo, DJ; Capodanno, D | 2 |
| Ardissino, D; Becker, RC; Budaj, A; Cannon, CP; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Khurmi, NS; Mahaffey, KW; Montgomery, D; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Yu, CM | 1 |
| Edwards, MG; O'Shea, JP; Starac, D; Waterer, GW; Whitmore, TJ | 1 |
| Aronson, D | 1 |
| Barnay, P; Bessereau, J; Bonello, L; Bultez, B; Chelini, V; Fournier, N; Gaubert, M; Gramond, C; Laine, M; Maillard, L; Mokrani, Z; Paganelli, F; Richard, T | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Bonello, L; Dignat-George, F; Frere, C; Guieu, R; Kipson, N; Mancini, J; Paganelli, F | 1 |
| Alexopoulos, D; Xanthopoulou, I | 1 |
| Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Bliden, KP; Gurbel, PA; Tantry, US | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Cattaneo, M; Nylander, S; Schulz, R | 1 |
| Elosua, R; Marrugat, J; Vila, J | 2 |
| Catalá-López, F | 1 |
| Daiber, A; Gori, T; Jurk, K; König, J; Krahn, U; Lackner, K; Munzel, T; Schnorbus, B; Warnke, S | 1 |
| Fortmann, SD; Serebruany, VL | 2 |
| Massberg, S; Sibbing, D | 1 |
| Harrington, RA; Himmelmann, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Bataille, V; Carrié, D; Garcia, C; Lhermusier, T; Lipinski, MJ; Mejean, S; Murat, G; Sié, P; Voisin, S | 1 |
| Musallam, A; Roguin, A | 1 |
| Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P | 1 |
| Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S | 1 |
| Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B | 1 |
| Maggioni, AP | 1 |
| Baek, YS; Kim, DH; Kim, SH; Kwan, J; Park, KS; Park, SD; Shin, SH; Woo, SI | 1 |
| Drucker, AG; Januzzi, JL; Manchette, AM | 1 |
| Catalano, HN; Criniti, JM; Izcovich, A; Popoff, F; Ruiz, JI | 1 |
| Schühlen, H | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Vanassche, T; Weitz, JI | 1 |
| Aylward, P; Brandrup-Wognsen, G; Brilakis, ES; Cannon, C; Claeys, MJ; Cools, F; Cornel, JH; Held, C; Himmelmann, A; James, SK; Kotsia, A; Lewis, BS; Meier, B; Steg, GP; Stevens, SR; Wallentin, L; Weaver, D | 1 |
| Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Delle Karth, G; Siller-Matula, JM | 1 |
| Alexopoulos, D; Bampouri, T; Gkizas, V; Koniari, I; Kontoprias, K; Perperis, A; Stavrou, K; Vogiatzi, C; Xanthopoulou, I | 1 |
| Becker, RC; Cannon, CP; Harrington, RA; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Mahaffey, KM; Pieper, KS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Gaglia, MA | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo Silberman, S; Sideris, G; Voicu, S | 1 |
| Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Morange, P; Pankert, M; Quilici, J | 1 |
| Dobesh, PP; Oestreich, JH | 1 |
| Coats, AJ; Francis, DP; Nijjer, SS | 1 |
| Bacchini, S; Bongo, AS; Brunelleschi, S; Cavallino, C; Lupi, A; Rametta, F; Rognoni, A; Rosso, R; Secco, GG; Veia, A | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L | 1 |
| Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Vengoechea, F | 1 |
| Alexopoulos, D; Angiolillo, DJ; Bliden, KP; Gurbel, PA; Storey, RF; Tantry, US; Xanthopoulou, I | 1 |
| Parodi, G; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Bultez, B; Champenois, A; Chelini, V; Dignat-George, F; Frère, C; Gaubert, M; Laine, M; Luigi, S; Mokrani, Z; Paganelli, F; Peyrol, M; Thuny, F; Toesca, R; Yvorra, S | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Brokopp, J; Erlinge, D; Kander, T; Lood, C; Schött, U | 1 |
| Bellemain-Appaix, A; Collet, JP; Montalescot, G; Silvain, J | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Lenti, MC; Lombardi, N; Matucci, R; Mugelli, A; Vannacci, A | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| Borges, M; Gouveia, M; Rikner, K; Trindade, R | 1 |
| Gaussem, P; Godier, A; Taylor, G | 1 |
| Cavallini, C; De Servi, S; Ferlini, M; Leonardi, S | 1 |
| Anderson, JL; Goto, S; Huo, Y; Jeong, YH; Levine, GN; Mega, JL; Smith, SC; Taubert, K | 1 |
| Goldberg, A; Halabi, M; Nordkin, I; Rosenfeld, I | 1 |
| Kornowski, R; Lerman-Shivek, H; Leshem-Lev, D; Lev, EI; Orvin, K; Perl, L; Rechavia, E; Vaduganathan, M; Zemer-Wassercug, N | 1 |
| Jiang, M; You, JH | 3 |
| Roffman, DS | 1 |
| Anstrom, KJ; Cannon, CP; Cowper, PA; Davidson-Ray, L; Harrington, RA; Janzon, M; Kaul, P; Levin, LÅ; Mark, DB; Nikolic, E; Pan, W; Wallentin, L | 1 |
| Hlatky, MA; Kazi, DS | 1 |
| Dhillon, S | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Morange, P; Pankert, M; Quilici, J; Verdier, V | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Kafkas, NV; Liakos, CI; Mouzarou, AG | 1 |
| Arnaud, L; Bonello, L; Cointe, S; Dignat-George, F; Frere, C; Guieu, R; Kerbaul, F; Laine, M; Lemesle, G; Mancini, J; Paganelli, F; Sabatier, F; Thuny, F | 1 |
| Cambronero-Sánchez, F; Flores-Blanco, PJ; Gómez-Molina, M; Guerrero-Pérez, E; López-Cuenca, A; Manzano-Fernández, S; Sánchez-Galian, MJ; Sánchez-Martínez, M; Valdés, M | 1 |
| Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R | 1 |
| Bonhomme, F; Bonvini, R; Fontana, P; Poncet, A; Reny, JL | 1 |
| Bednar, F; Knot, J; Maly, M; Motovska, Z; Ondrakova, M; Ulman, J | 1 |
| Åkerblom, A; Barratt, BJ; Becker, RC; Eriksson, N; Hagström, E; Husted, S; James, SK; Johansson, Å; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Syvänen, AC; Teng, R; Varenhorst, C; Voora, D; Wallentin, L | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 3 |
| Aires, D; Deibert, B; Fischer, R; Fraga, G; Gillihan, R; Gollub, S; Laarman, R; Maybrook, RJ | 1 |
| Choussat, R; Deblaise, J; Dubourg, O; Mansencal, N; Nicol, M | 1 |
| Alexopoulos, D; Pentara, I; Perperis, A; Stavrou, K; Vlassopoulou, N; Vogiatzi, C; Xanthopoulou, I | 1 |
| Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM | 1 |
| Bonello, L; Cluzel, M; Dignat-George, F; Frere, C; Gaubert, M; Guieu, R; Hasan, A; Kerbaul, F; Laine, M; Mancini, J; Michelet, P; Paganelli, F; Thuny, F | 1 |
| Berry, C; Corcoran, D; Hennigan, B; Layland, J; Oldroyd, KG; Watkins, S | 1 |
| Teng, R | 2 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 4 |
| DeKoven, M; Effron, MB; Frech-Tamas, F; Karkare, S; Larmore, C; Lu, J; Marrett, E; McCollam, P; Molife, C; Vetrovec, GW; Zhu, Y | 1 |
| Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ | 1 |
| Chua, T; Gruntowicz, D; Johnson, SG; Morlock, RJ | 1 |
| Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; DeGroat, C; Dunn, EC; Ferrante, E; Franchi, F; Guzman, LA; Muniz-Lozano, A; Rollini, F; Suryadevara, S; Zenni, MM | 1 |
| Bangalore, S; Bavishi, C; Messerli, FH; Panwar, S | 1 |
| Bernlochner, I; Braun, S; Goedel, A; Haller, B; Kastrati, A; Laugwitz, KL; Mayer, K; Morath, T; Plischke, C; Schulz, C; Schunkert, H; Schüpke, S; Siess, W | 1 |
| Lüscher, TF | 1 |
| Chong, AY; Qutub, MA; So, DY | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Bonello, L; Camoin-Jau, L; Dignat-George, F; Frere, C; Guieu, R; Laine, M; Noirot, F; Paganelli, F | 1 |
| Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T | 1 |
| Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J | 1 |
| Ahn, MS; Ahn, SG; Kang, YS; Kim, JY; Lee, JH; Lee, JW; Lee, SH; Park, B; Park, SW; Yoo, BS; Yoon, J; Youn, YJ | 1 |
| Effron, MB; Frech-Tamas, F; Keller, S; Marrett, E; McCollam, PL; Molife, C; Murphy, BR; Nair, KV; Nordstrom, BL; Page, RL; Simeone, JC; Vetrovec, GW; Zhu, YE | 1 |
| Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ | 1 |
| Braun, OÖ; Christersson, C; Grove, EL; Halvorsen, S; James, SK; Lindholm, D; Storey, RF; Varenhorst, C | 1 |
| Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| O'Donoghue, ML; Sarma, A | 1 |
| Kim, MH; Pokov, AN; Serebruany, VL; Tomek, A | 1 |
| Giusti, B; Grifoni, E; Marcucci, R | 1 |
| Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X | 1 |
| Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M | 1 |
| Abtan, J; Amour, J; Barthélémy, O; Brugier, D; Collet, JP; Kerneis, M; Leprince, P; Martin, R; Mercadier, A; Montalescot, G; O'Connor, SA; Silvain, J | 1 |
| Akca, B; Berger, R; Delle-Karth, G; Kreiner, G; Lang, IM; Maurer, G; Neunteufl, T; Siller-Matula, JM | 1 |
| Amico, A; Amico, F; Mazzoni, J; Moshiyakhov, M; Tamparo, W | 1 |
| DeKoven, M; Effron, MB; Karkare, S; Larmore, C; Lee, WC; Lieu, HD; Lu, J; Molife, C; Vetrovec, GW; Zhu, Y | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Sachdeva, A | 1 |
| Balta, S; Celik, T; Demir, M; Demirkol, S; Erdogan, S; Iyisoy, A; Ozturk, C; Unlu, M; Yildirim, AO | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Frantz, S; Hofmann, U | 1 |
| Ahmed, Z; Bhatti, S; Garg, A; Hakeem, A; Uretsky, BF | 1 |
| Ferro, A | 1 |
| Chava, S; Schneider, DJ | 1 |
| Grohé, C | 1 |
| Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Dong, XW; Dong, ZX; Guo, H; Kong, YH; Li, JQ; Li, Y; Liu, B; Pan, YJ; Shao, Q; Sheng, L; Shi, J; Sun, DH; Wang, DY; Xue, HJ; Xue, JY; Yang, HP; Zhang, L; Zhou, YY | 1 |
| Barbieri, L; Bellomo, G; Daffara, V; Luca, GD; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Suryapranata, H; Verdoia, M | 1 |
| Angiolillo, DJ; Carlson, G; Franchi, F; Khan, N; Mehran, R; Raveendran, G; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y | 1 |
| Kerneis, M; Montalescot, G; Silvain, J | 1 |
| Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB | 1 |
| Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX | 1 |
| Geissel, W | 1 |
| Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, I; Pentara, I; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R | 1 |
| Abdullabekova, R; Bitz, U; Taizhanova, D; Visternichan, O; Zhunussov, Y | 1 |
| Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM | 1 |
| Ruiz-Nodar, JM | 1 |
| Biscaglia, S; Campo, G; Ferrari, R; Pavasini, R; Tebaldi, M; Tumscitz, C | 1 |
| Baker, NC; Friehling, M; Nadour, W | 1 |
| Jain, N; Reilly, RF | 1 |
| Abunassar, J; Chong, AY; Hibbert, B; Le May, MR; Malhotra, N; Pourdjabbar, A; So, DY; Whitten, TA | 1 |
| Huynh, K | 1 |
| Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J | 1 |
| Katsi, V; Tousoulis, D; Toutouzas, K; Trantalis, G | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Ditmarsch, M; Held, P; Himmelmann, A | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Berbis, J; Bonello, L; Dignat-George, F; Frere, C; Kerbaul, F; Laine, M; Lemesle, G; Paganelli, F; Roch, A; Thuny, F | 1 |
| Cattaneo, M | 2 |
| Husted, S; Li, J; Storey, RF; Tang, W; Teng, R | 1 |
| Ding, P; Han, W; Jin, ZG; Liu, HL; Liu, Y; Luo, JP; Ma, DX; Wei, YJ; Yang, SL; Zhang, J | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
| Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC | 1 |
| Aydoğdu, S; Çelebi, ÖÖ | 1 |
| Aksakal, E | 1 |
| French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S | 1 |
| Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME | 1 |
| Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL | 1 |
| Alexopoulos, D; Bampouri, T; Bei, I; Chasapi, A; Davlouros, P; Hahalis, G; Vogiatzi, C; Xanthopoulou, I | 1 |
| Caiazzo, G; Carino, A; De Rosa, S; Filippis, C; Indolfi, C; Mongiardo, A; Polimeni, A; Sabatino, J; Sorrentino, S; Spaccarotella, C; Strangio, A; Torella, D | 1 |
| Khan, N | 1 |
| Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Berger, PB; Granger, CB | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| James, SK; Jernberg, T; Lagerqvist, B; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L | 1 |
| Althouse, AD; Conrad Smith, AJ; Khandhar, SJ; Kudaravalli, M; Lee, JS; Marroquin, OC; Mulukutla, SR; Schindler, JT; Sharbaugh, MS; Toma, C | 1 |
| Bhatt, DL; Pareek, M | 1 |
| Bhat, A; Pang, M; Wu, Y; Zhang, H; Zhang, Y; Zhao, Y; Zhuang, K | 1 |
| Balduini, A; Becker, RC; Björquist, A; Cattaneo, M; Di Buduo, CA; Femia, EA; Nylander, S; Storey, RF | 1 |
| Parker, WA; Storey, RF | 1 |
| Bancone, C; Biancari, F; Chocron, S; Dalén, M; De Feo, M; Dominici, C; Faggian, G; Fischlein, T; Gatti, G; Gherli, R; Gherli, T; Gulbins, H; Kinnunen, EM; Mariscalco, G; Maschietto, L; Maselli, D; Mignosa, C; Musumeci, F; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Svenarud, P; Verhoye, JP; Zanobini, M | 1 |
| Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R | 1 |
| Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW | 1 |
| Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A | 1 |
| Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
| Heuser, RR | 1 |
| Bernick, J; Chong, AY; Dick, A; Froeschl, M; Glover, C; Hibbert, B; Labinaz, M; Le May, MR; Lugomirski, P; Marquis, JF; Maze, R; Pourdjabbar, A; Ramirez, FD; Simard, T; So, DY; Wells, G | 1 |
| Alimohammadi, A; Buffon, A; Kolodziejczak, M; Lang, IM; Lip, GY; Navarese, EP; Siller-Matula, JM; Winter, MP | 1 |
| Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL | 1 |
| Chan, MY; Khoo, AL; Lim, BP; Lin, L; Teng, M; Wu, TS; Zhao, YJ | 1 |
| Bonaca, MP; Wiviott, SD | 1 |
| Storey, RF; Sumaya, W | 1 |
| Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU | 1 |
| Alexopoulos, D; Armylagos, S; Davlouros, P; Koutsogiannis, N; Moulias, A; Salata, P; Tsigkas, G; Xanthopoulou, I | 1 |
| Bian, S; Dong, P; Yang, X | 1 |
| Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C | 1 |
| Kola, N; Mattiello, G; Mirra, M; Morisco, C; Spinelli, L | 1 |
| Di Mario, C; Sorini Dini, C; Wijns, W | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Q; Xue, Y | 1 |
| Buser, PT; Haschke, M; Krisai, P; Mueller, C | 1 |
| Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J | 1 |
| Angiolillo, DJ; Franchi, F; Rollini, F | 2 |
| Chen, N; Ding, P; Liu, H; Wei, Y | 1 |
| Barbour, C; Gesheff, T | 1 |
| Alexopoulos, D; Barampoutis, N; Deftereos, S; Giannopoulos, G; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Perperis, A; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I | 1 |
| Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Berkovitch, A; Erez, A; Frydman, S; Katz, M; Kukuy, A; Matetzky, S; Mazin, I; Mazo, A; Narodistky, M; Regev, E; Sabbag, A; Segev, A | 1 |
| Angiolillo, DJ; Gaglia, MA; Kiramijyan, S; Lhermusier, T; Lipinski, MJ; Pokharel, S; Steinvil, A; Storey, RF; Torguson, R; Waksman, R; Wallentin, L | 1 |
| Crescioli, G; Lombardi, N; Lucenteforte, E; Mugelli, A; Vannacci, A | 1 |
| Hu, D; Li, C; Shen, X; Sun, Y; Tao, M; Wang, DW; Yu, T; Zhang, L; Zhang, X | 1 |
| Chan, R; Kong, SL; Kwok, J; Lee, S; Shea, C; Siu, D; Tam, CC; Tang, WH; Wong, A; Yung, A | 1 |
| Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Guzman, LA | 1 |
| Ball, SG; Greenwood, JP; Plein, S; Ridgway, JP; Sparrow, P; Younger, JF | 1 |
| Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK | 1 |
| Husted, S | 2 |
| Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Mitchell, P; Storey, RF | 1 |
| Doggrell, SA | 1 |
| Husted, S; van Giezen, JJ | 1 |
| Schömig, A | 1 |
| Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L | 1 |
| Alexopoulos, N; Anadiotis, AV; Janik, M; Lerakis, S; McLean, DS; Oshinski, JN; Stillman, AE; Veledar, E; Zaragoza-Macias, E | 1 |
| Collet, JP; Montalescot, G | 1 |
| Franchini, M; Mannucci, PM | 1 |
| Eshaghian, S; Kaul, S; Shah, PK | 1 |
| Bhatt, DL | 1 |
| Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J | 1 |
| del Río, A; Heras, M | 1 |
| Tomoda, H | 1 |
| Atar, D; Serebruany, VL | 2 |
| Parra, D; Rosenstein, RS | 1 |
| Lotfi, A; Rothberg, M; Wartak, SA | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Stone, GW | 1 |
| Anderson, SD; Epstein, BJ; Shah, NK; Yim, J | 1 |
| Angiolillo, DJ; Capodanno, D; Dharmashankar, K | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Davies, SL | 1 |
| Ashworth, A; El-Omar, M; Fath-Ordoubadi, F; Fraser, D; Horner, S; Mamas, MA; Millington, S; Neyses, L; Welch, E | 1 |
| Gratsianskiĭ, NA | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L | 1 |
| Montalescot, G; Silvain, J | 1 |
| Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D | 1 |
| Abu-Fadel, MS; Dib, C; Hanna, EB | 1 |
| Abbate, A; Agostoni, P; Angiolillo, DJ; Biondi-Zoccai, G; Gaita, F; Lotrionte, M; Romagnoli, E; Sangiorgi, G; Sheiban, I; Testa, L; Valgimigli, M | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L | 1 |
| Ardissino, D; Caracciolo, M; D'Urbano, M; De Servi, S | 1 |
| Morais, J | 1 |
| Radke, PW; Schunkert, H | 1 |
| Abergel, E; Nikolsky, E | 1 |
| Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD | 1 |
| Pollack, CV | 1 |
| Jilma, B; Siller-Matula, JM | 1 |
| Frey, N; Ivandic, B | 1 |
| Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J | 1 |
| Schneider, DJ | 1 |
| Hashemzadeh, M; Movahed, MR; Ramaraj, R | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M | 1 |
| Gaglia, MA; Waksman, R | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M | 1 |
| White, HD | 1 |
| Ohman, EM; Roe, MT | 1 |
| Becker, RC; Harrington, RA; James, SK; Wallentin, L | 1 |
| Hamad, B; Huber, K; Kirkpatrick, P | 1 |
| Berger, PB; Good, CW | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Deeks, ED | 1 |
| Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M | 1 |
| Cattaneo, GJ; Cattaneo, M; Podda, GM | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC | 1 |
| Böhm, M; Schirmer, SH | 1 |
| Fadda, V; Maratea, D; Messori, A; Passaro, D | 1 |
| Biddle, AK; Crespin, DJ; Federspiel, JJ; Jonas, DE; Rossi, JS | 1 |
| Timmis, A | 1 |
| Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L | 1 |
| Björkman, JA; Glaves, P; Kirk, I; Sidaway, J; van Giezen, JJ | 1 |
| Barbato, E; De Bruyne, B; Peace, A | 1 |
| Abbate, A; Agostoni, P; Biondi-Zoccai, G; D'Ascenzo, F; Modena, MG | 1 |
| Alber, HF; Frick, M; Huber, K; Pachinger, O | 1 |
| Becker, RC; Cairns, R; Cannon, CP; Cools, F; Cooper, A; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Khurmi, NS; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Choo, K; Chun, KJ; Faranesh, AZ; Han, D; Kim, J; Kim, JH; Kim, JS; Lederman, RJ; Park, JH; Park, YH; Song, SK | 1 |
| Hinneburg, I | 1 |
| Colucci, VJ; Crouch, MA; Howard, PA; Spinler, SA | 1 |
| Traynor, K | 1 |
| Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L | 1 |
| D'Urbano, M; De Servi, S; Navarese, EP; Savonitto, S | 1 |
| Chan, W; Duffy, SJ; Ellims, AH; Kaye, DM; Taylor, AJ | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Brilakis, ES; de Lemos, JA | 1 |
| Morrow, T | 1 |
| Akerblom, Å; Åsenblad, N; Becker, RC; Buck, K; Budaj, A; Giannitsis, E; Horrow, J; Husted, S; James, SK; Katus, HA; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Andreotti, F; Buffon, A; Castriota, F; Cremonesi, A; Gurbel, PA; Kozinski, M; Kubica, A; Kubica, J; Musumeci, G; Navarese, EP; Tavazzi, L | 1 |
| Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Braunwald, E | 1 |
| Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL | 1 |
| Janknegt, R; Ruiters, L; Ten Cate, H | 1 |
| Calvi, V; Capodanno, D; Tamburino, C | 1 |
| Belavic, JM | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA | 1 |
| Cheng, JW | 1 |
| James, S; Varenhorst, C | 1 |
| Armstrong, PW; Das, D; Fu, Y; James, S; Siha, H; Storey, RF; Wallentin, L; Westerhout, CM; Zheng, Y | 1 |
| Held, C | 1 |
| Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF | 1 |
| Verheugt, FW | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA | 1 |
| Díez, JG; Kuritzky, L | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Barn, K; Steinhubl, SR | 1 |
| Guan, L; Mu, Y; Quaglia, LA; Shih, MC; Tang, Q; Wang, C; Yang, L | 1 |
| Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I | 1 |
| Fukuda, H; Furuhashi, T; Hase, H; Joki, N; Kunimasa, T; Masai, H; Moroi, M; Sugi, K | 1 |
| Reed, SD | 1 |
| Burgess, S; Juergens, CP; Mallard, TA | 1 |
| Lincoff, AM; May, CH | 1 |
| Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L | 1 |
| Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D | 1 |
| Alström, U; Åsenblad, N; Becker, RC; Brandrup-Wognsen, G; Cannon, CP; Held, C; Hogue, CW; Horrow, J; James, S; Mahaffey, KW; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L | 1 |
| Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A | 1 |
| Lancellotti, P | 1 |
| Beer, J; Gebhard, C | 1 |
| Akerblom, A; Asenblad, N; Becker, RC; Budaj, A; Claeys, MJ; Horrow, J; Husted, S; James, SK; Katus, H; Siegbahn, A; Storey, RF; Wallentin, L | 1 |
| Aradi, D; Komócsi, A; Serebruany, VL; Vorobcsuk, A | 1 |
| Bevilacqua, M; Cirillo, P; D'Anna, C; De Rosa, R; Di Gioia, G; Galasso, G; Niglio, T; Piccolo, R; Piscione, F; Strisciuglio, T | 1 |
| Cenci, C; Cioni, G; Gensini, GF; Giusti, B; Lombardi, A; Marcucci, R | 1 |
| Htun, WW; Steinhubl, SR | 1 |
| Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L | 1 |
| Bonello, L; Laine, M; Paganelli, F | 1 |
| Massberg, S; Orban, M; Sibbing, D | 1 |
| Aronow, WS | 1 |
| Armstrong, PW; Westerhout, CM | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Lee, KW; Norell, MS | 1 |
131 review(s) available for adenosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2022 |
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Atrioventricular Block; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Vasodilator Agents | 2023 |
A review of the effects of ticagrelor on adenosine concentration and its clinical significance.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Equilibrative Nucleoside Transporter 1; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2021 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2017 |
The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Platelet Aggregation Inhibitors; Regression Analysis; Ticagrelor; Treatment Outcome | 2017 |
Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Observational Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2017 |
Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2017 |
Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.
Topics: Acute Coronary Syndrome; Adenosine; Cytochrome P-450 CYP2C19; Drug Interactions; Dyspnea; Half-Life; Hemorrhage; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |
Ticagrelor for the prevention of ischemic events in patients with prior myocardial infarction and peripheral artery disease.
Topics: Acute Coronary Syndrome; Adenosine; Government Regulation; Half-Life; Hemorrhage; Humans; Myocardial Infarction; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2018 |
Cost-effectiveness of ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Cost-Benefit Analysis; Drug Costs; Guideline Adherence; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Quality of Life; Quality-Adjusted Life Years; Ticagrelor; Time Factors; Treatment Outcome | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Double-Blind Method; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Drug Administration Schedule; Drug Costs; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; United States | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
Subgroup analyses with special reference to the effect of antiplatelet agents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Data Interpretation, Statistical; Humans; Israel; Piperazines; Platelet Aggregation Inhibitors; Population Groups; Prasugrel Hydrochloride; Reproducibility of Results; Thiophenes; Ticagrelor | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticagrelor | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Substitution; Genetic Testing; Humans; Piperazines; Polymorphism, Genetic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Humans; Hypothermia, Induced; Intensive Care Units; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Risk Assessment; Shock, Cardiogenic; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Humans; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Treatment Outcome | 2014 |
Ticagrelor: a novel drug for an old problem.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Humans; Patents as Topic; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Humans; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2014 |
Dyspnoea management in acute coronary syndrome patients treated with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy.
Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor: a review of its use in adults with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aging; Combined Modality Therapy; Coronary Artery Bypass; Evidence-Based Medicine; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Thrombosis; Ticagrelor | 2015 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Fractional flow reserve-guided management in stable coronary disease and acute myocardial infarction: recent developments.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Pressure Determination; Cardiac Imaging Techniques; Central Venous Pressure; Coronary Disease; Coronary Stenosis; Forecasting; Fractional Flow Reserve, Myocardial; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sex Factors; Vascular Resistance; Vasodilator Agents | 2015 |
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Clinical Trials as Topic; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2015 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Electrocardiography; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Stents; Ticagrelor; Ticlopidine | 2016 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Glomerular Filtration Rate; Hemorrhage; Humans; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Renal Insufficiency; Ticagrelor; Ticlopidine | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Sex Factors; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Role of T-cells in myocardial infarction.
Topics: Acute Coronary Syndrome; Adaptive Immunity; Adenosine; Animals; Cell Movement; Disease Models, Animal; Humans; Immunity, Innate; Lymphocyte Activation; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Signal Transduction; T-Lymphocytes | 2016 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Dialysis; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.
Topics: Acute Coronary Syndrome; Adenosine; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
[The use of ticagrelor in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Ticagrelor | 2013 |
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Ticagrelor: Effects Beyond the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Humans; Injections, Intravenous; Percutaneous Coronary Intervention; Platelet Aggregation; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
The year in cardiology 2016: coronary interventions.
Topics: Absorbable Implants; Acute Coronary Syndrome; Adenosine; Aftercare; Aged, 80 and over; Cardiac Imaging Techniques; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Fibrinolytic Agents; Fractional Flow Reserve, Myocardial; Graft Occlusion, Vascular; Humans; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prosthesis Design; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; ST Elevation Myocardial Infarction; Stents; Thrombectomy; Ticagrelor; Time-to-Treatment; Tissue Scaffolds | 2017 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Advances in antiplatelet therapy: agents in clinical development.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome | 2009 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Vasoconstriction | 2009 |
New antiplatelet agents: why they are needed.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
A new era for antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2010 |
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome | 2011 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Standard of Care; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Ticagrelor: a review of its use in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Humans; Multicenter Studies as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Update on anti-platelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Female; Humans; Hypertension; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Principles, current status and clinical implications of ischaemic heart disease assessment by cardiac magnetic resonance imaging.
Topics: Acute Coronary Syndrome; Adenosine; Contrast Media; Coronary Circulation; Defibrillators, Implantable; Edema, Cardiac; Gadolinium; Heart Function Tests; Humans; Magnetic Resonance Imaging; Microcirculation; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Organ Size; Preoperative Care; Reproducibility of Results; Vasodilator Agents | 2012 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Drug Interactions; Genotype; Humans; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine | 2011 |
Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Coronary Angiography; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Treatment Outcome | 2012 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Information Services; Drugs, Generic; Evidence-Based Medicine; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor | 2012 |
Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Atherosclerosis; Coronary Artery Disease; Drug Interactions; Humans; Pharmacogenetics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2012 |
Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Female; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2012 |
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Meeting new challenges with antiplatelet therapy in primary care.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Primary Health Care; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Platelet inhibitors in clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Interactions; Drug Resistance; Drugs, Investigational; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticagrelor | 2014 |
Antiplatelets in acute coronary syndrome: personal perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidol; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2012 |
Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome. Agents, indications, issues to consider in clinical practice.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Management of 'no-reflow' complicating reperfusion therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Balloon Occlusion; Coronary Angiography; Diagnosis, Differential; Filtration; Humans; Myocardial Reperfusion; Nitroprusside; No-Reflow Phenomenon; Prostheses and Implants; Vasodilator Agents; Verapamil | 2008 |
116 trial(s) available for adenosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial).
Topics: Acute Coronary Syndrome; Adenosine; Coronary Angiography; Coronary Circulation; Epinephrine; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Treatment Outcome | 2022 |
Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Epidermal Growth Factor; Humans; Interleukin-6; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Vessels; Endothelium; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2020 |
Cardiovascular magnetic resonance accurately detects obstructive coronary artery disease in suspected non-ST elevation myocardial infarction: a sub-analysis of the CARMENTA Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Disease; Coronary Stenosis; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Perfusion Imaging; Non-ST Elevated Myocardial Infarction; Predictive Value of Tests; Reproducibility of Results; Vasodilator Agents | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Impact of Timing on the Functional Recovery Achieved With Platelet Supplementation After Treatment With Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized,
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Endothelial Progenitor Cells; Female; Humans; Inflammation Mediators; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Seoul; Stents; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Renal Elimination; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Antiplatelet Effect of Different Loading Doses of Ticagrelor in Patients With Non-ST-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: The APELOT Trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome; Young Adult | 2017 |
[Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticlopidine | 2018 |
Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea.
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Cross-Over Studies; Drug Monitoring; Dyspnea; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors | 2018 |
Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Clopidogrel; Coronary Vessels; Cross-Over Studies; Endothelium, Vascular; Europe; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2018 |
METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angina, Unstable; Blood Platelets; Cells, Cultured; Drug Interactions; Female; Humans; Intestinal Absorption; Male; Metoclopramide; Middle Aged; Morphine; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2018 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drugs, Generic; Follow-Up Studies; Germany; Humans; Markov Chains; Models, Economic; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Quality-Adjusted Life Years; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Intravenous; Aged; Area Under Curve; Blood Flow Velocity; Coronary Circulation; Cross-Over Studies; Echocardiography, Doppler; Female; Greece; Humans; Least-Squares Analysis; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Single-Blind Method; Thiophenes; Ticagrelor; Treatment Outcome; Vasodilator Agents | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Quality of Life; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Time Factors | 2013 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; Coronary Circulation; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Humans; Internationality; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Endpoint Determination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Ticagrelor; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Survival Analysis; Ticagrelor; Treatment Outcome | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine | 2013 |
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; United Kingdom | 2014 |
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Diabetes Mellitus; Female; France; Humans; Hypoglycemic Agents; Insulin; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Pilot Projects; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentiation Factor 15; Hospital Mortality; Humans; Kaplan-Meier Estimate; Myocardial Revascularization; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Troponin T | 2014 |
Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2013 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, Liquid; Clopidogrel; Cyclic AMP; Erythrocytes; Female; Humans; Male; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REA
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Coronary Thrombosis; Drug Administration Schedule; Fibrinolytic Agents; Germany; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Stents; Stroke; Thiophenes; Ticagrelor; Time Factors; Time-to-Treatment; Treatment Outcome | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; Drug Synergism; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Ticlopidine | 2014 |
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Double-Blind Method; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Treatment Outcome | 2014 |
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Denmark; Humans; Purinergic P2Y Receptor Antagonists; Sweden; Ticagrelor; Ticlopidine | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Sex Factors; Stents; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, control
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxidative Stress; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Single-Blind Method; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Proportional Hazards Models; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2014 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary Vessels; Humans; Microcirculation; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Republic of Korea; Research Design; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Ultrasonography | 2014 |
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Electrocardiography; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Survival Rate; Ticagrelor; Treatment Outcome | 2014 |
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cause of Death; Clopidogrel; Confidence Intervals; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Topics: Acute Coronary Syndrome; Adenosine; Brazil; Clopidogrel; Cost-Benefit Analysis; Disease Management; Electrocardiography; Female; Germany; Health Care Costs; Humans; Male; Markov Chains; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Quality of Life; Quality-Adjusted Life Years; Secondary Prevention; Sweden; Ticagrelor; Ticlopidine; United Kingdom | 2015 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Severity of Illness Index; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2015 |
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antigens, CD34; Body Mass Index; Clopidogrel; Endothelial Progenitor Cells; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Cytochrome P-450 CYP3A; Female; Genome-Wide Association Study; Genotype; Glucuronosyltransferase; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome; Young Adult | 2015 |
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Double-Blind Method; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2015 |
Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Female; Hospitalization; Humans; Male; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2015 |
Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Blood Platelets; Cell Adhesion Molecules; France; Humans; Microfilament Proteins; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Immature platelet fraction and high-on treatment platelet reactivity with ticagrelor in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Ticagrelor | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Republic of Korea; Risk Factors; Stroke; Taiwan; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr.
Topics: Acute Coronary Syndrome; Adenosine; Caffeine; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Electrocardiography; Purinergic P1 Receptor Antagonists; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Postoperative Hemorrhage; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Transplantation, Homologous; Treatment Outcome | 2015 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Cardiac; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Preoperative Care; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Troponin | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Biological Availability; Female; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Tissue Distribution; White People; Young Adult | 2016 |
Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary In
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Function Tests; Preoperative Care; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Eptifibatide; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; New South Wales; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Substitution; Female; Gene Expression Regulation; Humans; Male; MicroRNAs; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Long Term Adverse Effects; Male; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Studies of the interaction of ticagrelor with the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; HEK293 Cells; Humans; Megakaryocytes; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Ticagrelor; Ticlopidine | 2016 |
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Over Studies; Drug Administration Schedule; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Ontario; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Adjustment; Ticagrelor; Treatment Outcome | 2016 |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Blood Platelets; Deglutition; Feasibility Studies; Female; Humans; Male; Mastication; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Gene Expression; Gene Frequency; Genotype; Genotyping Techniques; Humans; Male; Middle Aged; Mutation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2010 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Kidney Diseases; Male; Middle Aged; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Volume; Humans; Male; Middle Aged; Oxygen Consumption; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Respiratory Function Tests; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; Cystatin C; Double-Blind Method; Endpoint Determination; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Protein Precursors; Ticagrelor; Ticlopidine; Troponin I | 2012 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Analysis; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Troponin I; Troponin T | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myocardial Infarction; Outcome Assessment, Health Care; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Statistics as Topic; Ticagrelor; Ticlopidine; United States | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life Expectancy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Cross-Over Studies; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Smoking; Stents; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Europe; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Analysis of Variance; Biomarkers; Clopidogrel; Cystatin C; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Severity of Illness Index; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
271 other study(ies) available for adenosine and Acute Coronary Syndrome
| Article | Year |
|---|---|
FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
[Systemic inflammatory response syndrome associated with use of ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Systemic Inflammatory Response Syndrome; Ticagrelor | 2021 |
Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
Topics: Acute Coronary Syndrome; Adenosine; Diabetes Mellitus, Type 2; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Proteinase-Activated; Ticagrelor | 2022 |
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Renal Insufficiency; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Integrated Pharmacokinetics/Pharmacodynamics Model and Simulation of the Ticagrelor Effect on Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2023 |
IL-6 helps weave the inflammatory web during acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Humans; Interleukin-6; Mice; Myocardial Infarction; Myocardial Ischemia | 2023 |
Ticagrelor inverse agonist activity at the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Blood Platelets; Diphosphates; Drug Inverse Agonism; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2024 |
Interindividual Variations in the Adenosine-Induced Hemodynamics During Fractional Flow Reserve Evaluation: Implications for the Use of Quantitative Flow Ratio in Assessing Intermediate Coronary Stenoses.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angina, Stable; Biological Variation, Individual; Coronary Angiography; Coronary Stenosis; Female; Fractional Flow Reserve, Myocardial; Hemodynamics; Humans; Hyperemia; Male; Middle Aged; Vasodilator Agents | 2019 |
Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Artery Bypass; Female; Humans; Male; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor | 2020 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests | 2021 |
Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Follow-Up Studies; Humans; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
The FDA and PLATO Investigators death lists: Call for a match.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Suicide; Ticlopidine; Treatment Outcome | 2021 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2021 |
Coronary Collaterals Function and Clinical Outcome Between Patients With Acute and Chronic Total Occlusion.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiac Catheterization; Chronic Disease; Collateral Circulation; Coronary Occlusion; Coronary Vessels; Disease-Free Survival; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Risk Factors; Time Factors; Treatment Outcome; Vasodilator Agents | 2017 |
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Troponin | 2017 |
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk Factors; Shock, Cardiogenic; Slovenia; Survival Rate; Ticagrelor; Ticlopidine; Time Factors | 2018 |
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Retrospective Studies; Safety; Ticagrelor; Ticlopidine | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Streptokinase; Stroke; Ticagrelor; Ticlopidine; Tissue Plasminogen Activator | 2017 |
Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2017 |
Safety and Efficacy of Prasugrel and Ticagrelor in Acute Coronary Syndrome. Results of a "Real World" Multicenter Registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Coronary Care Units; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Ticagrelor; Treatment Outcome | 2017 |
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Disease Management; Female; Hospitalization; Humans; Hyperglycemia; Italy; Male; Middle Aged; Myocardial Revascularization; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Reversal of the platelet inhibitory effect of the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization Review; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbidity; Diabetes Mellitus; Female; Greece; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Proportional Hazards Models; Prospective Studies; Stroke; Ticagrelor; Ticlopidine | 2018 |
More Evidence for Non-P2Y
Topics: Acute Coronary Syndrome; Adenosine; Cross-Over Studies; Diabetes Mellitus; Endothelial Progenitor Cells; Humans; Inflammation; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Receptors, Purinergic P2Y12; Retrospective Studies; Secondary Prevention; Ticagrelor; Ticlopidine | 2017 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Withholding Treatment | 2017 |
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Italy; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Registries; Retrospective Studies; Ticagrelor; Ticlopidine | 2017 |
Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Medicare; Michigan; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Prognosis; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticagrelor; Time Factors; United States | 2017 |
The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Area Under Curve; China; Decision Support Techniques; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Reproducibility of Results; Risk Assessment; Risk Factors; ROC Curve; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Hemorrhage; Hospital Mortality; Humans; Italy; Logistic Models; Male; Middle Aged; Multivariate Analysis; Non-ST Elevated Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Association Between Ischemic and Bleeding Risk Scores and the Use of New P2Y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Drug Prescriptions; Female; Hemorrhage; Hospitalization; Humans; Male; Myocardial Ischemia; Patient Discharge; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Ticagrelor | 2018 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Is ticagrelor safe in intensive care unit patients? Focus on bradycardic events.
Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Critical Care; Humans; Intensive Care Units; Platelet Aggregation Inhibitors; Ticagrelor | 2018 |
One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database.
Topics: Acute Coronary Syndrome; Adenosine; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Treatment Outcome | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Decision-Making; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female; Gene Frequency; Genetic Predisposition to Disease; Hemorrhage; Heterozygote; Homozygote; Humans; Hypertension; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Precision Medicine; Retrospective Studies; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Disease-Free Survival; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Risk Factors; Thrombectomy; Ticagrelor; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2017 |
Perforated balloon technique: A simple and handy technique to combat no-reflow phenomenon in coronary system.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Circulation; Female; Humans; Male; Middle Aged; No-Reflow Phenomenon; Retrospective Studies; Treatment Outcome; Vasodilator Agents | 2018 |
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Community Pharmacy Services; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Delivery of Health Care, Integrated; Drug Costs; Female; Genetic Testing; Humans; Male; Markov Chains; Medication Therapy Management; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Point-of-Care Testing; Precision Medicine; Predictive Value of Tests; Program Evaluation; Quality of Life; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; United States | 2018 |
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prognosis; Prospective Studies; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2018 |
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine | 2018 |
Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asia; China; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Female; Health Care Costs; Hong Kong; Humans; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Republic of Korea; Taiwan; Ticagrelor; Ticlopidine | 2018 |
Unexpected Cardiac MRI Findings in Patients Presenting to the Emergency Department for Possible Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aortic Aneurysm; Aortic Dissection; Cardiac Imaging Techniques; Cardiomyopathies; Coronary Artery Disease; Emergency Service, Hospital; Exercise Test; Female; Heart Valve Diseases; Humans; Incidental Findings; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Myocarditis; Pericarditis; Pleural Effusion; Prospective Studies; Vasodilator Agents | 2018 |
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Costs and Cost Analysis; Female; Health Care Costs; Humans; Length of Stay; Male; Middle Aged; Patient Acceptance of Health Care; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Period; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor; Ticlopidine | 2018 |
Metabolism of ticagrelor in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Female; Humans; Linear Models; Male; Middle Aged; Morphine; Platelet Aggregation Inhibitors; Prospective Studies; Regression Analysis; Smoking; ST Elevation Myocardial Infarction; Ticagrelor | 2018 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2018 |
Prognostic value of a new semiquantitative score system for adenosine stress myocardial perfusion by CMR.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arrhythmias, Cardiac; Coronary Artery Disease; Female; Heart Failure; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Prognosis | 2019 |
Evaluation of platelet activity by multiple electrode impedance aggregometry in acute coronary syndromes: pilot study in a Brazilian tertiary-care public hospital.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Electric Impedance; Female; Hospitals, Public; Humans; Male; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Tertiary Care Centers | 2019 |
Routine Fractional Flow Reserve Measurement After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angina, Stable; Cardiac Catheterization; Coronary Angiography; Coronary Artery Disease; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Male; Middle Aged; Percutaneous Coronary Intervention; Predictive Value of Tests; Prospective Studies; Recurrence; Registries; Risk Factors; Stents; Time Factors; Treatment Outcome; Vasodilator Agents | 2019 |
[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2019 |
[Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality of Life; Retrospective Studies; Ticlopidine | 2019 |
Exploring the ticagrelor-statin interplay in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Simvastatin; Ticagrelor; Ticlopidine | 2013 |
[Gastrointestinal bleeding after treatment with ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointestinal Hemorrhage; Humans; Pulmonary Disease, Chronic Obstructive; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Potential benefits of ticagrelor beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists | 2013 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Humans; Male; Markov Chains; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor immediately prior to stenting is associated with smaller residual thrombus in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Care; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thrombosis; Ticagrelor | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Industry; Drugs, Generic; Forecasting; Germany; Humans; National Health Programs; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Prospective Studies; Purinergic P2 Receptor Antagonists; Ticagrelor | 2013 |
Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Medicine; Guideline Adherence; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; United States | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Letter by Serebruany and DiNicolantonio regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials".
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benefit Analysis; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Coagulation Tests; Blood Platelets; Cost-Benefit Analysis; Decision Trees; Europe; Humans; Incidence; Markov Chains; Medication Adherence; Monte Carlo Method; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2014 |
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Revascularization; Ticagrelor; Ticlopidine | 2014 |
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Australia; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Genotype; Humans; Markov Chains; Ticagrelor; Ticlopidine | 2013 |
Coronary flow reserve with a turbo: a warning for the use of adenosine as a provocative test in patients receiving ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2014 |
Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and
Topics: Acute Coronary Syndrome; Adenosine; Endpoint Determination; Humans; Platelet Aggregation Inhibitors; United States Food and Drug Administration | 2014 |
Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Quality of Life; Ticlopidine | 2014 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy.
Topics: Acute Coronary Syndrome; Adenosine; Cohort Studies; Dose-Response Relationship, Drug; Greece; Humans; Medication Adherence; Platelet Activation; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Ticagrelor as an alternative in clopidogrel-associated neutropenia.
Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Discrepancies in the primary PLATO trial publication and the FDA reviews.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Congresses as Topic; Humans; Information Dissemination; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2014 |
Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary Circulation; Double-Blind Method; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Reproducibility of Results; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biopsy; Coronary Artery Bypass; Diagnosis, Differential; Hemoptysis; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Purinergic P2Y Receptor Antagonists; Ticagrelor; Tomography, X-Ray Computed | 2014 |
Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Dyspnea; Female; Follow-Up Studies; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2014 |
Reply: Adenosine plasma concentration increase by ticagrelor in patients with acute coronary syndrome: no cause for fear in clinical practice.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Purinergic P2Y Receptor Antagonists | 2014 |
Adenosine plasma concentration increase by ticagrelor in patients with acute coronary syndrome: no cause for fear in clinical practice.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Purinergic P2Y Receptor Antagonists | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome".
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Evaluation of comparative treatment effects using indirect comparisons. Response.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2013 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Drug Utilization; Evidence-Based Medicine; Humans; Japan; Marketing; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Economic Competition; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; Drug Utilization; Evidence-Based Medicine; Humans; International Cooperation; Marketing; Patient Satisfaction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Letter by Roguin and Musallam regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Stents; Ticlopidine | 2014 |
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Stents; Ticlopidine | 2014 |
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Models, Economic; Poland; Secondary Prevention; State Medicine; Ticagrelor; Ticlopidine | 2014 |
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Administration Schedule; Humans; Medication Adherence; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Clopidogrel; Drug Hypersensitivity; Female; Humans; Male; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Ticlopidine | 2014 |
[Ticagrelor in acute coronary syndrome. Explaining the inexplicable].
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Conflict of Interest; Evidence-Based Medicine; Financial Support; Humans; Publication Bias; Risk Factors; Ticagrelor; Treatment Outcome; United States; United States Food and Drug Administration | 2014 |
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2014 |
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up:
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Information Dissemination; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticlopidine; United States Food and Drug Administration | 2014 |
Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition?
Topics: Acute Coronary Syndrome; Adenosine; Cause of Death; Clopidogrel; Female; Humans; Male; Ticagrelor; Ticlopidine | 2014 |
Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Treatment Outcome | 2014 |
Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Postoperative Care; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Recurrence; Retrospective Studies; Thiophenes; Thrombosis; Ticagrelor | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Response to letter regarding, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome".
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 2014 |
Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Body Mass Index; Female; Humans; Male; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2014 |
Protecting the pipeline of science: openness, scientific methods and the lessons from ticagrelor and the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Bias; Humans; Peer Review, Research; Publishing; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Research Design; Scientific Misconduct; Ticagrelor; United States; United States Food and Drug Administration | 2014 |
COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Combined Modality Therapy; Female; Hemostasis; Homeostasis; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor-related dyspnea: an underestimated and poorly managed event?
Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Female; Humans; Male; Medication Adherence; Purinergic P2Y Receptor Antagonists | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Economic evaluation of ticagrelor for secondary prevention following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Humans; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor | 2015 |
Inefficacy of platelet transfusion to reverse ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antidotes; Fatal Outcome; Humans; Male; Platelet Count; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2015 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Societies, Medical; Thiophenes; Ticagrelor; Ticlopidine; World Health Organization | 2014 |
Life-threatening complete atrioventricular block associated with ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Atrioventricular Block; Cardiac Pacing, Artificial; Electrocardiography; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Female; Follow-Up Studies; Humans; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors | 2015 |
A delicate balance: the cost effectiveness of new antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Drug Monitoring; Female; Humans; Kidney Function Tests; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Statistics as Topic; Ticagrelor; Treatment Outcome | 2015 |
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Dyspnea; Female; Humans; Incidence; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Ticagrelor | 2015 |
Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: An ex vivo study.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Angiography; Drug Design; Female; Humans; Male; Middle Aged; Patient Admission; Percutaneous Coronary Intervention; Platelet Count; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Ticagrelor; Ticlopidine | 2015 |
Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Blood Platelets; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Predictive Value of Tests; Stents; Thrombosis; Ticagrelor | 2016 |
Ticagrelor-induced acute generalized exanthematous pustulosis.
Topics: Acute Coronary Syndrome; Acute Generalized Exanthematous Pustulosis; Adenosine; Aged; Biopsy; Clopidogrel; Drug Eruptions; Female; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Side effects of ticagrelor: Sinus node dysfunction with ventricular pause.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Electrocardiography; Heart Ventricles; Humans; Male; Purinergic P2Y Receptor Antagonists; Sick Sinus Syndrome; Sinoatrial Node; Ticagrelor | 2015 |
Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cross-Sectional Studies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Dyspnea; Female; Health Services; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Ticagrelor | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Genetic Testing; Genotype; Humans; Managed Care Programs; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Conflict of Interest; Humans; Peer Review; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Selection Bias; Ticagrelor; Ticlopidine | 2015 |
Mitral valve disease and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Cardiac Catheterization; Humans; Mitral Valve Insufficiency; Myocardial Infarction; Percutaneous Coronary Intervention; Polymorphism, Single Nucleotide; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Blood Platelets; Drug Administration Schedule; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Republic of Korea; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; White People | 2015 |
One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Anticoagulants; Comorbidity; Female; Health Services; Hemorrhage; Humans; Male; Middle Aged; Patient Readmission; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Retrospective Studies; Ticagrelor | 2015 |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Blood Platelets; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Genotype; Health Care Costs; Heterozygote; Humans; Middle Aged; Pharmacogenetics; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2015 |
PHILO -- ensuring trial results are not lost in translation.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Female; Germany; Humans; Male; Non-ST Elevated Myocardial Infarction; Prevalence; Purinergic P2Y Receptor Antagonists; Risk Factors; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Biomarkers; Blood Platelets; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Ticagrelor; Treatment Outcome | 2016 |
The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticlopidine | 2016 |
"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Chi-Square Distribution; Comorbidity; Databases, Factual; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Propensity Score; Retrospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; United States | 2016 |
Current Antiplatelet Agents in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
The progressed atrioventricular block associated with ticagrelor therapy may not require permanent pacemaker after acute coronary syndrome; it may be reversible.
Topics: Acute Coronary Syndrome; Adenosine; Atrioventricular Block; Electrocardiography; Heart Rate; Humans; Male; Middle Aged; Pacemaker, Artificial; Prognosis; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Fractional flow reserve in acute coronary syndrome: a word of caution.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Cardiac Catheterization; Coronary Thrombosis; Drug-Eluting Stents; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Male; Percutaneous Coronary Intervention; Predictive Value of Tests; Reproducibility of Results; Tomography, Optical Coherence; Vasodilator Agents | 2015 |
Newer antiplatelet agents in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Therapy, Combination; Dyspnea; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2016 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
[Advantages of Ticagrelor outweigh also in COPD patients].
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Pulmonary Disease, Chronic Obstructive; Ticlopidine | 2016 |
Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Comorbidity; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor; Treatment Outcome | 2016 |
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Sex Characteristics; Ticagrelor; Ticlopidine | 2016 |
Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Percutaneous Coronary Intervention; Preoperative Care; Ticlopidine; Troponin | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Female; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2016 |
[How long should therapy last?].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; Humans; Long-Term Care; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Greece; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
OPTIMUM APPLICATION OF MODERN ANTITHROMBOTIC DRUGS AMONG PATIENTS WITH THE ACUTE CORONARY SYNDROME WITH THE RISK OF STRICTURE FORMATION OF CORONARY ARTERIES.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Coronary Restenosis; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Ticagrelor | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angiography; Cause of Death; Clopidogrel; Comorbidity; Drug Substitution; Female; Health Care Surveys; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Registries; Risk Factors; Ticagrelor; Ticlopidine | 2016 |
Clinically significant ticagrelor induced conduction abnormalities following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Atrioventricular Block; Coronary Angiography; Drug-Eluting Stents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Ticagrelor; Treatment Outcome | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Anticonvulsants; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Administration Schedule; Drug Interactions; Epilepsy; Female; Humans; Male; Middle Aged; Registries; Ticagrelor; Treatment Outcome | 2016 |
Antiplatelet therapy: Ticagrelor reduces cardiac events in patients with PAD or diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2016 |
Editorial on PEGASUS - TIMI 54.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Drug Costs; Humans; Middle Aged; Percutaneous Coronary Intervention; Pharmacogenomic Testing; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Quality-Adjusted Life Years; Ticagrelor; Ticlopidine | 2016 |
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Pilot Projects; Platelet Activation; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ticagrelor; Ticlopidine | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Lack of Evidence for Deterioration in Endothelial Function Following Ticagrelor Treatment Cessation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Drug Administration Schedule; Endothelium, Vascular; Evidence-Based Medicine; Female; Humans; Hyperemia; Male; Manometry; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors; Treatment Outcome; Vasodilation | 2016 |
Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Registries; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Understanding the Adverse Effects of Ticagrelor in Practice.
Topics: Acute Coronary Syndrome; Adenosine; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Thrombosis; Databases, Factual; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Complications; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Risk Assessment; Sweden; Ticagrelor | 2016 |
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medication Therapy Management; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2016 |
Ticagrelor for patients with acute coronary syndromes: PLATOnic affair or lasting SWEDEHEART?
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2016 |
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Treatment Outcome | 2016 |
ACS Treatment Continues to Improve: But Price Matters.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Treatment Outcome | 2016 |
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Coronary Angiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proprotein Convertase 9; Ticagrelor; Treatment Outcome | 2017 |
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Assessment; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Singapore; Ticagrelor | 2016 |
Prasugrel Versus Ticagrelor: Uncertainty Remains.
Topics: Acute Coronary Syndrome; Adenosine; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome; Uncertainty | 2016 |
Effect of High (200 μg/kg per Minute) Adenosine Dose Infusion on Fractional Flow Reserve Variability.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arterial Pressure; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Infusions, Intravenous; Male; Middle Aged; Nitroglycerin; Prospective Studies; Vasodilator Agents | 2016 |
Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Epidemiologic Studies; Female; Humans; Latin America; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2017 |
Spontaneous coronary artery dissection in a young woman with polycystic ovarian syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Coronary Vessels; Electrocardiography; Female; Humans; Platelet Aggregation Inhibitors; Polycystic Ovary Syndrome; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2017 |
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Outcome Assessment; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; Clopidogrel; Cyclic AMP; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2017 |
Ticagrelor induced systemic inflammatory response syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged, 80 and over; Follow-Up Studies; Humans; Male; Purinergic P2Y Receptor Antagonists; Systemic Inflammatory Response Syndrome; Ticagrelor | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y
Topics: Acute Coronary Syndrome; Adenosine; Drug Interactions; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine | 2017 |
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Asian People; Cell Adhesion Molecules; Clopidogrel; Cryopreservation; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Vasodilator Agents | 2018 |
Dyspnea in patients treated with P2Y
Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Female; Greece; Hematocrit; Hemorrhage; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Black People; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; White People | 2017 |
Ticagrelor safety profile in real-life setting of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Humans; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Coma; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Cardiovascular magnetic resonance of scar and ischemia burden early after acute ST elevation and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Contrast Media; Coronary Circulation; Exercise Test; Female; Gadolinium DTPA; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Predictive Value of Tests; Prospective Studies; Severity of Illness Index | 2008 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor, a platelet aggregation inhibitor for the potential prevention and treatment of arterial thrombosis and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Structure-Activity Relationship; Thrombosis; Ticagrelor; Treatment Outcome | 2009 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
Prognostic value of adenosine stress cardiovascular magnetic resonance in patients with low-risk chest pain.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Angina Pectoris; Chest Pain; Coronary Stenosis; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Discharge; Patient Readmission; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Time Factors | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intracranial Hemorrhages; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Research Design; Ticagrelor; Ticlopidine | 2009 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dose-Response Relationship, Drug; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Animals; Clinical Trials as Topic; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2010 |
Resting Pd/Pa measured with intracoronary pressure wire strongly predicts fractional flow reserve.
Topics: Acute Coronary Syndrome; Adenosine; Aorta; Blood Pressure; Cardiac Catheterization; Cohort Studies; Coronary Circulation; Coronary Stenosis; Coronary Vessels; Female; Humans; Hyperemia; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; ROC Curve; Severity of Illness Index; Vasodilator Agents | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Male; Pharmacogenetics; Phenotype; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Chronic Disease; Hemorrhage; Humans; Kidney Diseases; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor | 2010 |
[The PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2010 |
Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Cyclic N-Oxides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Ticagrelor; Ticlopidine | 2010 |
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2011 |
Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Postoperative Hemorrhage; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.
Topics: Acute Coronary Syndrome; Adenosine; Bias; Clinical Trials as Topic; Clopidogrel; Europe; Humans; Mortality; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Epidemiologic Research Design; Europe; Humans; Patient Selection; Practice Guidelines as Topic; Statistics as Topic; Survival Analysis; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Clopidogrel; Europe; Genetic Predisposition to Disease; Humans; Research Design; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2011 |
Fresh from the pipeline. Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor | 2011 |
Anti-platelet treatments in acute coronary syndrome: simplified network meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor | 2011 |
Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Cost-Benefit Analysis; Genotype; Humans; Markov Chains; Medicare; Platelet Aggregation Inhibitors; Secondary Prevention; Ticagrelor; United States | 2011 |
Non-interventional management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cell Line; Cell Line, Tumor; Coronary Circulation; Dipyridamole; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; Hyperemia; Male; Purinergic P2Y Receptor Antagonists; Rats; Ticagrelor | 2012 |
The reconciliation of pressure and light: a clinical case of complementary use of fractional flow reserve and optical coherence tomography.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Exercise Test; Fractional Flow Reserve, Myocardial; Humans; Male; Nitroglycerin; Tomography, Optical Coherence; Vasodilator Agents | 2011 |
Agreement between adjusted indirect comparison and simplified network meta-analyses on prasugrel and ticagrelor (Reply to Passaro et al. - Int J Cardiol 2011).
Topics: Acute Coronary Syndrome; Adenosine; Humans; Piperazines; Randomized Controlled Trials as Topic; Thiophenes | 2011 |
Pressure-wire based assessment of microvascular resistance using calibrated upstream balloon obstruction: a predictor of myocardial viability.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Blood Pressure; Calibration; Cardiac Catheterization; Cardiac Catheters; Chi-Square Distribution; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Linear Models; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardium; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Sensitivity and Specificity; Stents; Tissue Survival; Transducers, Pressure; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2012 |
P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Dyspnea; Humans; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor | 2011 |
Ticagrelor approved for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Ticagrelor. Acute coronary syndromes: nothing new.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2011 |
Benefits of ticagrelor debated as antiplatelet class approaches generic market.
Topics: Acute Coronary Syndrome; Adenosine; Drugs, Generic; Humans; Platelet Aggregation Inhibitors; Ticagrelor; United States | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2012 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Data Interpretation, Statistical; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Risk Assessment; Risk Factors; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Ticagrelor: a new option for ACS.
Topics: Acute Coronary Syndrome; Adenosine; Drug Approval; Humans; Multicenter Studies as Topic; Myocardial Reperfusion; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2012 |
Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Humans; Multicenter Studies as Topic; Peripheral Arterial Disease; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Ticagrelor | 2012 |
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpretation, Statistical; Disclosure; Humans; Informed Consent; Multicenter Studies as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Research Support as Topic; Selection Bias; Ticagrelor; Ticlopidine; Treatment Refusal; United States; United States Food and Drug Administration | 2011 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; Stroke; Ticagrelor; Ticlopidine | 2012 |
Effectiveness of myocardial contrast echocardiography quantitative analysis during adenosine stress versus visual analysis before percutaneous therapy in acute coronary pain: a coronary artery TIMI grading comparing study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Analysis of Variance; Coronary Angiography; Echocardiography; Female; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Pain; Reproducibility of Results; Sensitivity and Specificity; Severity of Illness Index | 2012 |
The predictive value of chronic kidney disease for assessing cardiovascular events under consideration of pretest probability for coronary artery disease in patients who underwent stress myocardial perfusion imaging.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angina, Unstable; Chi-Square Distribution; Coronary Artery Disease; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Predictive Value of Tests; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Assessment; Risk Factors; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
How country-specific should a country-specific cost-effectiveness analysis be?
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Warfarin | 2013 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2012 |
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor | 2012 |
[Medication of the month. Ticagrelor (Brilique): potent oral antagonist of platelet activity].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2012 |
Ticagrelor: the silence of the platelets.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
The power of more than one.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2013 |